The role of neoadjuvant chemotherapy for breast cancer treatment

被引：50

作者：

Ikeda T. ^{[1
]}

Jinno H. ^{[1
]}

Matsui A. ^{[2
]}

Masamura S. ^{[3
]}

Kitajima M. ^{[1
]}

机构：

[1] Department of Surgery, Keio University, School of Medicine, Shinjuku-ku, Tokyo 160-8582

来源：

Breast Cancer | 2002年 / 9卷 / 1期

关键词：

Breast cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy;

D O I：

10.1007/BF02967540

中图分类号：

学科分类号：

摘要：

Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.

引用

页码：8 / 14

页数：6

共 41 条

[1]

Goldie J.H., Coldman A.J., A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treatment Reports, 63, 11-12, pp. 1727-1733, (1979)

[2]

Fisher B., Gunduz N., Saffer E.A., Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases, Cancer Research, 43, 4, pp. 1488-1492, (1983)

[3]

Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz Jr. A.B., Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D., Effect of preoperative chemotherapy on the outcome of women with operable breast cancer, Journal of Clinical Oncology, 16, 8, pp. 2672-2685, (1998)

[4]

Mauriac L., MacGrogan G., Avril A., Durand M., Floquet A., Debled M., Dilhuydy J.M., Bonichon F., Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up, Annals of Oncology, 10, 1, pp. 47-52, (1999)

[5]

Makris A., Powles T.J., Ashley S.E., Chang J., Hickish T., Tidy V.A., Nash A.G., Ford H.T., A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Annals of Oncology, 9, 11, pp. 1179-1184, (1998)

[6]

Scholl S.M., Fourquet A., Asselain B., Pierga J.Y., Vilcoq J.R., Durad J.C., Dorval T., Palangie T., Jouve M., Beuzeboc P., Garcio-Giralt E., Salmon R.J., De La Rochefordiere A., Campana F., Pouillart P., Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6, European Journal of Cancer Part A: General Topics, 30, 5, pp. 645-652, (1994)

[7]

Jakesz R., Comparison of pre-vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Study Group (ABCSG) Trial 7. #125, Proc Am Soc Clin Oncol, (2001)

[8]

Gradishar W.J., Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer, Oncology, 11, 8 SUPPL., pp. 15-18, (1997)

[9]

Morrell L.E., Lee Y.J., Hurley J., Arias M., Mies C., Richman S.P., Fernandez H., Donofrio K.A., Raub Jr. W.A., Cassileth P.A., A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma, Cancer, 82, 3, pp. 503-511, (1998)

[10]

Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., Zambetti M., Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute, Journal of Clinical Oncology, 16, 1, pp. 93-100, (1998)

← 1 2 3 4 5 →